TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

24 Jun 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH

14 Jun 2021 06:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH

13 Jun 2021 16:00:00 By Nasdaq GlobeNewswire

Terns to Present at the UBS Global Healthcare Virtual Conference & Participate in the J.P. Morgan Biotech 2021 CEO Conference Call Series

19 May 2021 16:00:00 By Nasdaq GlobeNewswire

Terns Reports First Quarter 2021 Financial Results and Provides Corporate Update

13 May 2021 15:05:03 By Nasdaq GlobeNewswire

Terns to Present at the 19th Annual Virtual Needham HealthCare Conference

07 Apr 2021 06:05:00 By Nasdaq GlobeNewswire

Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

30 Mar 2021 15:05:01 By Nasdaq GlobeNewswire

Terns Announces Initiation of Dosing in Phase 1 Clinical Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment of NASH

22 Mar 2021 06:35:00 By Nasdaq GlobeNewswire

Terns to Present on VAP-1 and FXR at NASH-TAG Conference 2021

08 Mar 2021 06:00:00 By Nasdaq GlobeNewswire

Terns to Present at the Cowen 41st Annual Health Care Conference

23 Feb 2021 15:35:00 By Nasdaq GlobeNewswire